Year: 2010

Scientific-proof for the DC Court of Appeals that life begins at conception? Not by a long shot

The DC Appeals Court hears oral arguments today in the case over whether the federal government can legally fund embryonic stem cell (ESC) research. At stake are dozens of research projects that could provide treatments or cures for millions of Americans. Reportedly, an amicus brief to the court has been filed on behalf of Associate …

Scientific-proof for the DC Court of Appeals that life begins at conception? Not by a long shot Read More »

From genes to chemicals: iPS cell field, reprogramming in transition

FaviconIPSCELL

Sheng Ding’s lab reports today in Cell Stem Cell (you can read it here) that they have replaced all genetic factors in a new iPS cell reprogramming method except Oct4. The other factors were replaced by chemical compounds. Thus, we continue a major transition in the iPS cell field away from genes and toward chemicals. …

From genes to chemicals: iPS cell field, reprogramming in transition Read More »

Stem Cells and Cars

It happens several times a month these days. Some new, interesting paper comes out on IPS cells or on transdifferentiation. Immediately, opponents of ES cell research criminally twist the findings in the new paper and produce ‘news’ headlines that pop up high on Google to the effect that ES cells are now ‘obsolete’. IPS cells …

Stem Cells and Cars Read More »

Great news: FDA gives ACT the green light bringing hope to millions of people with blindness

advanced-cell-technology

The FDA has given Advanced Cell Technology (ACT) the go ahead to begin their clinical trial using retinal progenitor cells derived from hESC by clearing the company’s IND application, bringing hope to those with vision loss and even blindness. The trial will be a combined Phase I/II to treat Stargardt’s Macular Dystrophy and has huge …

Great news: FDA gives ACT the green light bringing hope to millions of people with blindness Read More »

The trouble with teratoma: a stem cell paradox

Teratoma

The trouble with the risk of teratoma presents a stem cell paradox. Stem cells possess two traits lacking in other cells: self-renewal and pluripotency. This duo of defining functions is key to the ability of stem cells to be used to treat patients via regenerative medicine. A paradox exists because while self-renewal and pluripotency are both …

The trouble with teratoma: a stem cell paradox Read More »